Oral Anticoagulants in Liver Disease: Not Child's Play

Affiliations

¹ Boston University School of Medicine, Boston, Massachusetts. Electronic address: ehylek@bu.edu.
² Division of Gastroenterology and Inborn Error Products, Center for Drug Evaluation and Research, Office of New Drugs/ODE III, U.S. Food and Drug Administration, Silver Spring, Maryland.

Free article

Editorial

Elaine M Hylek et al. J Am Coll Cardiol. 2019.

Free article

. 2019 Jul 2;73(25):3309-3311.

doi: 10.1016/j.jacc.2019.05.009.

¹ Boston University School of Medicine, Boston, Massachusetts. Electronic address: ehylek@bu.edu.
² Division of Gastroenterology and Inborn Error Products, Center for Drug Evaluation and Research, Office of New Drugs/ODE III, U.S. Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Keywords: atrial fibrillation; cirrhosis; direct oral anticoagulant; liver disease; non-vitamin K oral antagonist; warfarin.

Comment on

Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease.
Lee SR, Lee HJ, Choi EK, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Lee SR, et al. J Am Coll Cardiol. 2019 Jul 2;73(25):3295-3308. doi: 10.1016/j.jacc.2019.04.052. J Am Coll Cardiol. 2019. PMID: 31248551